RDEA-119

(BAY-869766; N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide)

Purity > 99.0 %

RDEA119 is an orally bioavailable potent (IC50 at low nM), selective MEK inhibitor with potential anti-cancer activity. RDEA119 specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.

RDEA119 is in phase I/II clinical trials for the treatment of advanced cancer and for the treatment of inflammation.

Free Shipping within the Continental USA